Adolfo Favaretto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1521372/publications.pdf

Version: 2024-02-01

87	4,838	147566	95083
papers	citations	31 h-index	68 g-index

90	90	90	5534
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. Journal of the National Cancer Institute, 2003, 95, 362-372.	3.0	768
2	Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Nonâ€"Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. Journal of Clinical Oncology, 2005, 23, 6865-6872.	0.8	452
3	Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 2006, 24, 1443-1448.	0.8	276
4	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2015, 33, 2667-2674.	0.8	237
5	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Nonâ€"Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology, 2012, 30, 3002-3011.	0.8	229
6	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics, 2014, 46, 844-849.	9.4	208
7	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 435-444.	5.2	172
8	Long-term survival and prognostic factors in thymic epithelial tumoursâ˜†. European Journal of Cardio-thoracic Surgery, 2004, 26, 412-418.	0.6	141
9	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 4647-4659.	3.2	130
10	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. Journal of Clinical Oncology, 2018, 36, 342-349.	0.8	120
11	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 1379-1388.	5.1	119
12	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. British Journal of Cancer, 2008, 99, 51-56.	2.9	107
13	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncology, The, 2007, 8, 500-512.	5.1	89
14	Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. British Journal of Cancer, 2013, 109, 552-558.	2.9	89
15	Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of a Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxisâ€"A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study. Journal of Clinical Oncology, 2005, 23, 569-575.	0.8	85
16	Long term results of surgery and chemotherapy in small cell lung cancer1. European Journal of Cardio-thoracic Surgery, 1998, 14, 398-402.	0.6	77
17	Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Nonâ€"Small-Cell Lung Cancer: The MILES-2P Studies. Journal of Clinical Oncology, 2007, 25, 4663-4669.	0.8	77
18	Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Research, 2001, 11, 189-196.	0.6	70

#	Article	IF	Citations
19	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 799-811.	5.1	56
20	Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Nonâ€“Small-Cell Lung Cancer: Results of a Phase II-III Study. Journal of Clinical Oncology, 2006, 24, 681-687.	0.8	55
21	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutationâ€“Positive NSCLC Patients. Journal of Thoracic Oncology, 2020, 15, 80-90.	0.5	55
22	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Annals of Oncology, 2011, 22, 1528-1534.	0.6	52
23	Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer Research, 2014, 34, 493-501.	0.5	49
24	Effects of Sulfonylureas on Tumor Growth: A Review of the Literature. Oncologist, 2013, 18, 1118-1125.	1.9	48
25	Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. Critical Reviews in Oncology/Hematology, 2016, 97, 220-230.	2.0	43
26	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Nonâ€“Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. Clinical Cancer Research, 2017, 23, 3316-3324.	3.2	43
27	Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial. Journal of Thoracic Oncology, 2007, 2, 221-229.	0.5	42
28	Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Research Notes, 2012, 5, 482.	0.6	39
29	The Genotype for <scp>DPYD</scp> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. Clinical Pharmacology and Therapeutics, 2019, 105, 994-1002.	2.3	39
30	Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Research, 2010, 30, 5121-8.	0.5	37
31	Long-Term Results of Surgical Management of Pulmonary Metastases from Renal Cell Carcinoma. Thoracic and Cardiovascular Surgeon, 2006, 54, 544-547.	0.4	35
32	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. Lung Cancer, 2012, 76, 457-464.	0.9	32
33	Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. British Journal of Cancer, 2014, 111, 220-226.	2.9	31
34	Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer in Elderly Patients. Journal of Thoracic Oncology, 2014, 9, 733-737.	0.5	28
35	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 665-672.	0.5	28
36	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer, 1990, 65, 2631-2634.	2.0	27

#	Article	IF	Citations
37	Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer, 2003, 89, 1013-1021.	2.9	27
38	Molecular Targets in Malignant Pleural Mesothelioma Treatment. Current Drug Targets, 2009, 10, 1235-1244.	1.0	26
39	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. Current Drug Targets, 2011, 12, 922-933.	1.0	25
40	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 166-170.	1.1	25
41	Pemetrexed single agent in previously treated non-small cell lung cancer: A multi-institutional observational study. Lung Cancer, 2008, 60, 240-245.	0.9	24
42	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs, 2011, 71, 2231-2246.	4.9	23
43	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	0.5	23
44	An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma. Cancer Treatment Reviews, 2013, 39, 10-17.	3.4	23
45	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget, 2013, 4, 1572-1581.	0.8	23
46	Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer: Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. Cancer, 1993, 72, 697-706.	2.0	21
47	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. BMC Cancer, 2016, 16, 312.	1.1	21
48	Overview on ongoing or planned clinical trials in Europe. Lung Cancer, 2005, 49, S117-S121.	0.9	20
49	Treatment of Unfit Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Definition Criteria According an Expert Panel. Clinical Lung Cancer, 2015, 16, 399-405.	1.1	20
50	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. Oncotarget, 2015, 6, 42053-42066.	0.8	20
51	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Critical Reviews in Oncology/Hematology, 2004, 51, 171-189.	2.0	19
52	Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Nonâ€“Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01). Clinical Lung Cancer, 2014, 15, 258-265.	1.1	19
53	Results of surgical resection after induction chemoradiation for Pancoast tumours. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 805-812.	0.5	19
54	Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. Cancer, 1991, 68, 975-980.	2.0	16

#	Article	IF	Citations
55	Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. Interactive Cardiovascular and Thoracic Surgery, 2014, 19, 256-262.	0.5	16
56	Ultrarapid High-Dose Course of Prophylactic Cranial Irradiation in Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 84-90.	0.6	16
57	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study. European Journal of Cancer, 2021, 147, 120-127.	1.3	15
58	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget, 2017, 8, 32626-32638.	0.8	14
59	Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor. Annals of Hematology, 1993, 66, 185-193.	0.8	13
60	Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2010, 37, 1464-1469.	0.6	13
61	HLA-G 3â€²UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 1366.	1.8	13
62	Stanford V Regimen plus Consolidative Radiotherapy Is an Effective Therapeutic Program for Bulky or Advanced-Stage Hodgkinâ€™s Disease. Acta Haematologica, 2004, 112, 141-147.	0.7	12
63	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience. Lung Cancer, 2011, 73, 351-355.	0.9	12
64	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. American Journal of Case Reports, 2015, 16, 782-789.	0.3	10
65	Second and third line treatment in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 117-126.	2.0	9
66	Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2014, 9, 1008-1017.	0.5	9
67	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. Current Clinical Pharmacology, 2018, 13, 76-84.	0.2	9
68	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. Future Oncology, 2018, 14, 1347-1354.	1.1	9
69	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1783-1793.	1.2	8
70	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. Lung Cancer, 2016, 96, 52-55.	0.9	8
71	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. Frontiers in Pharmacology, 2018, 9, 1101.	1.6	8
72	Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial. Cancer, 1996, 78, 1701-1707.	2.0	7

#	Article	IF	Citations
73	Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience. Lung Cancer, 2010, 68, 228-233.	0.9	7
74	Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. European Journal of Cancer, 1993, 29, 704-708.	1.3	6
75	A Pilot Study of Concomitant Radiation and Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 264-267.	0.6	6
76	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. Oncotarget, 2016, 7, 25050-25063.	0.8	6
77	Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. Journal of Thoracic Oncology, 2012, 7, 233-242.	0.5	5
78	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist, 2019, 24, e318-e326.	1.9	5
79	Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). Anticancer Research, 2012, 32, 5393-9.	0.5	5
80	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. OncoTargets and Therapy, 2016, 9, 3671.	1.0	3
81	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer, 2016, 100, 30-37.	0.9	3
82	EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 2457-2464.	0.5	3
83	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020â€“Sep 2020; Sep 2020â€“May 2021) in the Veneto Oncology Network: The ROVID study. European Journal of Cancer, 2022, 167, 81-91.	1.3	3
84	Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesotheliomaâ€. European Journal of Cardio-thoracic Surgery, 2013, 44, 104-110.	0.6	2
85	Valutazione economica in base allo studio NAVOTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. Pharmacoeconomics Italian Research Articles, 2014, 16, 1.	0.2	2
86	Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer. Anticancer Research, 2015, 35, 2183-9.	0.5	2
87	Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study. Lung Cancer, 2014, 86, 47-53.	0.9	0